Published in Am J Epidemiol on January 01, 2001
Establishing the National Chlamydia Screening Programme in England: results from the first full year of screening. Sex Transm Infect (2004) 2.92
Modelling the effectiveness of chlamydia screening in England. Sex Transm Infect (2006) 1.95
Modelling the impact and cost-effectiveness of the HIV intervention programme amongst commercial sex workers in Ahmedabad, Gujarat, India. BMC Public Health (2007) 1.57
What is the achievable effectiveness of the India AIDS Initiative intervention among female sex workers under target coverage? Model projections from southern India. Sex Transm Infect (2006) 1.24
Modelling the cost effectiveness of rapid point of care diagnostic tests for the control of HIV and other sexually transmitted infections among female sex workers. Sex Transm Infect (2006) 1.23
Developing a realistic sexual network model of chlamydia transmission in Britain. Theor Biol Med Model (2006) 1.22
Evaluation design of a systematic, selective, internet-based, Chlamydia screening implementation in the Netherlands, 2008-2010: implications of first results for the analysis. BMC Infect Dis (2010) 1.21
Interventions for increasing chlamydia screening in primary care: a review. BMC Public Health (2007) 1.08
Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling. Sex Transm Infect (2006) 1.07
Chlamydial infection: an accurate model for opportunistic screening in general practice. Sex Transm Infect (2003) 1.03
How robust are the natural history parameters used in chlamydia transmission dynamic models? A systematic review. Theor Biol Med Model (2014) 0.91
Individual and population level effects of partner notification for Chlamydia trachomatis. PLoS One (2012) 0.90
Age- and gender-specific estimates of partnership formation and dissolution rates in the Seattle sex survey. Ann Epidemiol (2010) 0.89
Modeling secondary level of HIV contact tracing: its impact on HIV intervention in Cuba. BMC Infect Dis (2010) 0.81
Determinants of sexual network structure and their impact on cumulative network measures. PLoS Comput Biol (2012) 0.81
Effects of population based screening for Chlamydia infections in the Netherlands limited by declining participation rates. PLoS One (2013) 0.80
Insights in public health: The hidden epidemic: sexually transmitted diseases in 2014. Hawaii J Med Public Health (2014) 0.80
Population movement can sustain STI prevalence in remote Australian indigenous communities. BMC Infect Dis (2013) 0.79
Estimating age-dependent per-encounter chlamydia trachomatis acquisition risk via a Markov-based state-transition model. J Clin Bioinforma (2014) 0.78
Disease dynamics and costly punishment can foster socially imposed monogamy. Nat Commun (2016) 0.78
Exploring short-term responses to changes in the control strategy for Chlamydia trachomatis. Comput Math Methods Med (2012) 0.77
Cost-effectiveness analysis of Chlamydia trachomatis screening in Dutch pregnant women. Pathog Glob Health (2016) 0.77
Optimizing strategies for population-based chlamydia infection screening among young women: an age-structured system dynamics approach. BMC Public Health (2015) 0.75
Barriers and opportunities for evidence-based health service planning: the example of developing a Decision Analytic Model to plan services for sexually transmitted infections in the UK. BMC Health Serv Res (2012) 0.75
A Risk-based Model for Predicting the Impact of using Condoms on the Spread of Sexually Transmitted Infections. Infect Dis Model (2017) 0.75
Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens. Sex Transm Infect (2001) 2.85
Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J Clin Epidemiol (1996) 2.18
[Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women]. Ned Tijdschr Geneeskd (1999) 1.94
Decreasing STD incidence and increasing condom use among Chinese sex workers following a short term intervention: a prospective cohort study. Sex Transm Infect (2002) 1.83
Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang (2002) 1.80
The value of ProMED-mail for the Early Warning Committee in the Netherlands: more specific approach recommended. Euro Surveill (2008) 1.66
Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. Hum Reprod Update (2009) 1.64
Partner referral by patients with gonorrhea and chlamydial infection. Case-finding observations. Sex Transm Dis (1997) 1.60
Do gender differences in CD4 cell counts matter? AIDS (1999) 1.54
Estimation and prediction of the HIV-AIDS-epidemic under conditions of HAART using mixtures of incubation time distributions. Stat Med (2008) 1.44
[Cost-effectiveness of influenza vaccination The Netherlands]. Ned Tijdschr Geneeskd (1997) 1.39
Rabid puppy-dog imported into the Netherlands from Morocco via Spain, February 2012. Euro Surveill (2012) 1.38
Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach. Sex Transm Dis (2000) 1.37
Which factors are important in adults' uptake of a (pre)pandemic influenza vaccine? Vaccine (2009) 1.21
Differences in progression to AIDS between injection drug users and homosexual men with documented dates of seroconversion. Epidemiology (1996) 1.21
HIV prevalence, sexual risk behaviour and sexual mixing patterns among migrants in Amsterdam, The Netherlands. AIDS (1999) 1.19
Major improvements in cost effectiveness of screening women for Chlamydia trachomatis using pooled urine specimens and high performance testing. Sex Transm Infect (2002) 1.18
Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. Virology (1998) 1.18
Diagnostic accuracy of culture-based and PCR-based detection tests for methicillin-resistant Staphylococcus aureus: a meta-analysis. Clin Microbiol Infect (2011) 1.13
Pregnancies before and after HIV diagnosis in a european cohort of HIV-infected women. European Study on the Natural History of HIV Infection in Women. AIDS (2000) 1.12
HIV prevalence and risk behavior among injecting drug users who participate in "low-threshold" methadone programs in Amsterdam. Am J Public Health (1992) 1.11
The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. Eur J Clin Microbiol Infect Dis (2012) 1.08
Estimating influenza-related hospitalization in The Netherlands. Epidemiol Infect (1998) 1.06
[Benefit of the serological screening program for syphilis in pregnant women in Amsterdam in the period 1985-1989]. Ned Tijdschr Geneeskd (1991) 0.99
COPD in the working age population: the economic impact on both patients and government. COPD (2013) 0.97
Cost-effectiveness estimates for antenatal HIV testing in the Netherlands. Int J STD AIDS (2008) 0.96
Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels. J Clin Microbiol (1998) 0.96
HIV surveillance among sexually transmitted disease clinic attenders in Amsterdam, 1991-1996. AIDS (1998) 0.93
Determinants of high-risk sexual behavior among immigrant groups in Amsterdam: implications for interventions. J Acquir Immune Defic Syndr (2001) 0.93
The economics of HIV vaccines: projecting the impact of HIV vaccination of infants in sub-Saharan Africa. Pharmacoeconomics (2001) 0.92
Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis. Value Health (2001) 0.90
Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med (1999) 0.89
Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program. Vaccine (2001) 0.88
Health economic methodology illustrated with recent work on Chlamydia screening: the concept of extended dominance. Sex Transm Infect (2007) 0.88
HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations. Curr Pharm Des (2008) 0.87
Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine (2004) 0.87
Migrant injecting users: characteristics of Italian drug users living in Amsterdam. Subst Use Misuse (1996) 0.86
Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands. Aliment Pharmacol Ther (2006) 0.86
Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther (2003) 0.86
Bedside practice of blood transfusion in a large teaching hospital in Uganda: An observational study. Asian J Transfus Sci (2009) 0.86
Lifetime hospitalization profiles for symptomatic, HIV-infected persons. Health Policy (1996) 0.85
Excess drug prescriptions during influenza and RSV seasons in the Netherlands: potential implications for extended influenza vaccination. Vaccine (2008) 0.84
Evaluation of a risk assessment questionnaire to assist hepatitis C screening in the general population. Euro Surveill (2010) 0.84
Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany. Eur J Med Res (2010) 0.83
Cost-effectiveness of screening for genital Chlamydia trachomatis. Expert Rev Pharmacoecon Outcomes Res (2001) 0.83
Sexual risk behaviour among Surinamese and Antillean migrants travelling to their countries of origin. Sex Transm Infect (2005) 0.83
Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands. Vaccine (2012) 0.82
The pharmacists' potential to provide targets for interventions to optimize pharmacotherapy in patients with asthma. Int J Clin Pharm (2013) 0.82
Evaluating interventions to improve somatic health in severe mental illness: a systematic review. Acta Psychiatr Scand (2013) 0.82
The impact of introducing patient co-payments in Germany on the use of IVF and ICSI: a price-elasticity of demand assessment. Hum Reprod (2009) 0.81
Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin Ther (2003) 0.81
[Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population in Amsterdam. III. Cost-effectiveness analysis of screening women and the role of reinfection and partner treatment]. Ned Tijdschr Geneeskd (1999) 0.81
The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life. AIDS Care (2008) 0.80
[Screening for asymptomatic Chlamydia trachomatis infection in pregnancy; cost-effectiveness favorable at a minimum prevalence rate of 3% or more]. Ned Tijdschr Geneeskd (2000) 0.80
Geographical variation in disease progression in HIV-1 seroconverted injecting drug users in Europe? Int J Epidemiol (1999) 0.80
Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: An evaluation study in Belgium. Hum Vaccin Immunother (2015) 0.80
Costs of chemotherapy in the treatment of colorectal cancer. Eur J Health Econ (2006) 0.80
Modelling the impact of extended vaccination strategies on the epidemiology of pertussis. Epidemiol Infect (2011) 0.80
Comparing cost effectiveness of screening women for Chlamydia trachomatis in systematic and opportunistic approaches. Sex Transm Infect (2002) 0.79
Comparative impact assessment of AIDS: between doomsday and complacency. AIDS (1996) 0.79
Has the rate of progression to AIDS changed in recent years? AIDS (1997) 0.78
The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach. Vaccine (2007) 0.78
Hepatitis C virus serotype-specific core and NS4 antibodies in injecting drug users participating in the Amsterdam cohort studies. J Clin Microbiol (1998) 0.78
[Dutch Institute for Health Care Improvement revised guideline, 'Sexually transmitted diseases and neonatal herpes']. Ned Tijdschr Geneeskd (2003) 0.78
Gender differences in clinical manifestations before AIDS diagnosis among injecting drug users. Eur J Epidemiol (1998) 0.77
Altered P53 conformation. Int J Oncol (1997) 0.77
Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort design. Curr Med Res Opin (2015) 0.77
Cost-effectiveness of leucocyte-depleted erythrocyte transfusion in cardiac valve surgery. Transfus Med (2005) 0.77
Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam. AIDS (2001) 0.77
A population based dynamic approach for estimating the cost effectiveness of screening for Chlamydia trachomatis. Sex Transm Infect (2003) 0.77
RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population. Vaccine (2013) 0.76
Differential time preferences for money and quality of life. Pharmacoeconomics (2014) 0.76
[Splenectomy and pneumococcal vaccination]. Ned Tijdschr Geneeskd (2003) 0.75
Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. Aliment Pharmacol Ther (2002) 0.75
Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account. Vaccine (2013) 0.75
Economic evaluations of adult pneumococcal vaccination strategies. Expert Rev Pharmacoecon Outcomes Res (2001) 0.75
AIDS impact scenarios: questions for the years to come. AIDS (1990) 0.75
Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerations. Eur J Health Econ (2004) 0.75
Seroconversion to HIV-1 negative regulation factor. Lancet (1988) 0.75
Pharmacoeconomics of Helicobacter pylori: eradication versus maintenance therapy in controlling peptic ulcer disease. Expert Rev Pharmacoecon Outcomes Res (2001) 0.75
[Treatment with infliximab in patients with Crohn disease; experience in 132 patients]. Ned Tijdschr Geneeskd (2002) 0.75
Pharmacoeconomic evaluation of intensified antiretroviral treatment strategies in HIV/AIDS. Expert Rev Pharmacoecon Outcomes Res (2001) 0.75
A partial explanation for the low number of vertically acquired AIDS cases in Amsterdam, The Netherlands. AIDS (1997) 0.75
[Screening for Chlamydia trachomatis infection: which target group and at what price?]. Ned Tijdschr Geneeskd (1999) 0.75
Incidence of HTLV-I/II infection in seronegative high-risk individuals. J Med Virol (1993) 0.75